Todd Pitts, PhD

Associate Professor, Medicine-Medical Oncology

FacultyPhoto
Graduate Schools
  • MS, University of Arizona (2001)
  • PhD, University of Torino, Italy (2016)
Undergraduate School
  • BS, University of Arizona (AZ) (1996)
Department
Medicine-Medical Oncology

Professional Titles

  • Associate Professor

Publications

  • Development and characterization of predictive markers to the IGF-1R inhibitor, PQIP, in colorectal cancer (CRC). T.M. Pitts, S.A. Kaufman, J.J. Tentler, S. Leong, C.D. Coldren, F.R. Hirsch, M. Varella-Garcia, S.G. Eckhardt, 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Geneva, Switzerland 21?24 October 2008
  • Development of predictive markers of responsiveness to the MEK 1/2 Inhibitor AZD6244 in Colorectal Cancer (CRC) S. Nallapareddy, J.J. Tentler, C.D. Coldren, T.M. Pitts, S.A. Kaufman, S.G. Eckhardt, 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Geneva, Switzerland 21?24 October 2008
  • ENMD-2076 exerts antiangiogenic and antiproliferative activity against human colorectal cancer (CRC) xenograft models. J.J. Tentler, E.L.B. Pierce, N.J. Serkova, T.M. Pitts, M.R. Bray, G.C. Fletcher, S.G. Eckhardt, 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Geneva, Switzerland 21?24 October 2008
  • Vorinostat sensitizes colorectal cancer cell (CRC) lines to AZD6244 and results in synergistic inhibitory effects on proliferation. M.P. Morelli, A.M. Meyer, J.J. Tentler, T.M. Pitts, S. Nallapareddy, P.D. Smith, S.G. Eckhardt, 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Geneva, Switzerland 21?24 October 2008
  • Development and characterization of predictive markers of sensitivity to the IGF-1R inhibitor, OSI-906, in colorectal cancer (CRC). T.M. Pitts, A.C. Tan, G. Kulikowski, J.J. Tentler, A.M. Meyer, S.A. Kaufman, S. Leong, C.D. Coldren, F.R. Hirsch, M. Varella-Garcia, S.G. Eckhardt
  • Development of an Integrated Genomic Classifier for a Novel Agent in Colorectal Cancer: Approach to Individualized Therapy in Early Development Todd Pitts Aik Choon Tan Gillian Kulikowski John Tentler Amy Brown Sara Flanigan Stephen Leong Christopher Coldren Fred Hirsch Marileila Varella-Garcia Christopher Korch S. Gail Eckhardt. Clinical Cancer Research 2010 Accepted
  • A Novel Multi-Targeted Aurora A and VEGFR2 Kinase Inhibitor, ENMD-2076, Demonstrates Synergistic Antiproliferative and Proapoptotic Effects in Combination with Chemotherapy and Trastuzumab in Breast Cancer Cell Lines. Jennifer R. Diamond1, S. Gail Eckhardt1, Todd M. Pitts1, Blair C. Britt1, Maria I. Kachaeva1, Marileila Varella-Garcia1, Mark R. Bray2, Graham C. Fletcher2, and John J. Tentler1. 1Division of Medical Oncology, University of Colorado Denver Anschutz Medical Campus, Aurora CO; 2EntreMed, Inc., Toronto, Ontario Canada. AACR/EORTC 2009 Boston MA
  • Members of the Non-canonical WNT Pathway Confer Resistance to the MEK 1/2 Inhibitor AZD6244 in Colorectal Cancer (CRC) Cell Lines John J. Tentler, Sujatha Nallapareddy, Aik Choon Tan, Anna Spreafico, Sara A. Flanigan, Todd M. Pitts, and S. Gail Eckhardt Division of Medical Oncology, University of Colorado, Denver Anschutz Medical Campus, Aurora, CO.AACR/EORTC 2009 Boston MA
  • MicroRNA (miRNA) expression patterns as potential biomarkers of responsiveness to the MEK1/2 inhibitor, AZD6244, in Colorectal Cancer (CRC) Cell Lines Anna Spreafico, Aik Choon Tan, John J. Tentler, Sujatha Nallapareddy, Todd M. Pitts, S. Gail Eckhardt. Division of Medical Oncology, University of Colorado at Denver, Anschutz Medical Campus, Aurora, CO AACR/EORTC 2009 Boston MA
  • Rational combination of the IGF-1R/IR tyrosine kinase inhibitor (TKI), OSI-906, with the MEK inhibitor, U0126, results in synergistic and apoptotic effects in human colorectal cancer (CRC) cell lines Sara A. Flanigan1, Todd M. Pitts1, Gillian N. Kulikowski1, Aik Choon Tan1, Sujatha Nallapareddy1, John J. Tentler1, S. Gail Eckhardt1, Elizabeth Rizzo2, Stephen Leong1. 1Division of Medical Oncology, University of Colorado at Denver, Anschutz Medical Campus Aurora, CO, 2OSI Pharmaceuticals Inc., Melville, NY AACR/EORTC 2009 Boston MA
  • Targeting vascular endothelial growth factor receptor-1 and -3 with cediranib (AZD2171): effects on migration and invasion of gastrointestinal cancer cell lines. Morelli MP, Brown AM, Pitts TM, Tentler JJ, Ciardiello F, Ryan A, Jürgensmeier JM, Eckhardt SG. Mol Cancer Ther. 2009 Sep;8(9):2546-58. Epub 2009 Sep 15.
  • Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian Breast Cancer Family Study. Christopher Korch Tim Byers Todd Pitts Efang Li Margaret McCredie Graham Giles John Hopper Melissa Southey Cancer Research 2010 Accepted
  • Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian Breast Cancer Family Study. Mouchawar J, Korch C, Byers T, Pitts TM, Li E, McCredie MR, Giles GG, Hopper JL, Southey MC. Cancer Res. 2010 Jun 15;70(12):4795-800. Epub 2010 May 25.
  • Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer. Tentler JJ, Nallapareddy S, Tan AC, Spreafico A, Pitts TM, Morelli MP, Selby HM, Kachaeva MI, Flanigan SA, Kulikowski GN, Leong S, Arcaroli JJ, Messersmith WA, Eckhardt SG. Mol Cancer Ther. 2010 Dec;9(12):3351-62. Epub 2010 Oct 5.
  • The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models. Flanigan SA, Pitts TM, Eckhardt SG, Tentler JJ, Tan AC, Thorburn A, Leong S. Clin Cancer Res. 2010 Nov 15;16(22):5436-46. Epub 2010 Oct 13.
  • Phase I Safety, Pharmacokinetic and Pharmacodynamic Study of ENMD-2076, a Novel Angiogenic and Aurora Kinase Inhibitor, in Patients with Advanced Solid Tumors. Diamond JR, Bastos BR, Hansen RJ, Gustafson DL, Eckhardt SG, Kwak E, Pandya SS, Fletcher GC, Pitts TM, Kulikowski GN, Morrow M, Arnott J, Bray MR, Sidor CF, Messersmith WA, Shapiro GI. Clin Cancer Res. 2010 Dec 3. [Epub ahead of print]
  • Evaluation of Antiproliferative and Apoptotic Effects of the Rational Combination of the MEK1/2 Inhibitor Selumetinib (AZD6244) and Inhibitors of the Hedgehog Pathway in Colorectal Cancer (CRC) Cell Lines Anna Spreafico, John J. Tentler, Aik Choon Tan, Todd M. Pitts, Maria I. Kachaeva, Heather M. Selby, Jeffrey L. Brown*, Paul D. Smith**, S. Gail Eckhardt Division of Medical Oncology, University of Colorado at Denver, Anschutz Medical Campus, Aurora, CO; *AstraZeneca Pharmaceuticals, Waltham , MA USA; **Macclesfield, UK
  • Contribution of the Epithelial-to-Mesenchymal (EMT) Phenotype to the Sensitivity of Colorectal Cancer Cell Lines to the p21-Activated Kinase Inhibitor, PF-3758309 Eun Kyung Im1, Todd M Pitts1, Gillian N Kulikowski1, Aik Choon Tan1, Kelly McPhillips1, John J Tentler1, Brion W Murray2, William Carley2, Tod Smeal2, Chuangxing Guo2, S. Gail Eckhardt1 1Division of Medical Oncology, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado, 2Pfizer Global Research and Development, La Jolla Laboratories, San Diego, CA, USA
  • The Combination of PF-03084014 (a ?-secretase inhibitor) and Irinotecan Reduces ALDH+ Tumor-Initiating Cells and Recurrence in Tumors with Elevated Notch Pathway R. Powell, W. Messersmith, M. Varella-Garcia, A.Tan, B. Touban, T.M. Pitts, A. Dasari, J. Arcaroli University of Colorado Cancer Center, Aurora, CO
  • Diamond JR, Eckhardt SG, Tan AC, Newton TP, Selby HM, Brunkow KL, Kachaeva MI, Varella-Garcia M, Pitts TM, Bray MR, Fletcher GC, Tentler JJ. Predictive Biomarkers of Sensitivity to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Breast Cancer Models. Clin Cancer Res. 2013 Jan 1;19(1):291-303.
  • Bradshaw-Pierce EL, Pitts TM, Kulikowski G, Selby H, Merz AL, Gustafson DL, Serkova NJ, Eckhardt SG and Weekes C. Utilization of Quantitative In Vivo Pharmacology Approaches to Assess Combination Effects of Everolimus and Irinotecan in Mouse Xenograft Models of Colorectal Cancer. (Accepted in PLoS ONE: In Production).
  • Pitts TM, Kulikowski GN, Tan AC, Murray BW, Arcaroli JJ, Tentler JJ, Spreafico A, Selby HM, Kachaeva MI, McPhillips KL, Britt BC, Bradshaw-Pierce EL, Messersmith WA, Varella-Garcia M, and Eckhardt SG. Association of the Epithelial-to-Mesenchymal Transition (EMT) Phenotype with Responsiveness to the p21-Activated Kinase Inhibitor, PF-3758309, in Colon Cancer Models. (Accepted in Frontiers in Pharmacology of Anti-Cancer Drugs)
  • Bradshaw-Pierce EL, Pitts TM, Tan AC, McPhillips KL, Halsey C, Gustafson DL, Nguyen L, West M, Fisher T, Lee NV, Kan JLC, Murray BW, Eckhardt SG. Tumor p-glycoprotein correlates with efficacy of PF-3758309 in in vitro and in vivo models of colorectal cancer. (Accepted in Frontiers in Pharmacology of Anti-Cancer Drugs)
  • Pitts TM, Davis SL, Eckhardt SG, Bradshaw-Pierce EL. Targeting nuclear kinases in cancer: Development of cell cycle kinase inhibitors. Pharmacol Ther. 2013 Dec 19. [Epub ahead of print] PubMed PMID: 24362082
  • Flanigan SA, Pitts TM, Newton TP, Kulikowski GN, Tan AC, McManus MC, Spreafico A, Kachaeva MI, Selby HM, Tentler JJ, Eckhardt SG, Leong S. Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models. Clin Cancer Res. 2013 Nov 15;19(22):6219-29. PubMed PMID: 24045180
  • Pitts TM, Davis SL, Eckhardt SG, Bradshaw-Pierce EL. Targeting nuclear kinases in cancer: development of cell cycle kinase inhibitors. Pharmacol Ther. 2014 May;142(2):258-69. PubMed PMID: 24362082
  • Song EK, Tai W, Messersmith WA, Bagby S, Purkey A, Quackenbush KS, Pitts TM, Wang G, Blatchford P, Yahn R, Kaplan J, Tan AC, Atreya CE, Eckhardt G, Kelley RK, Venook A, Kwak EL, Ryan D, Arcaroli JJ. Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model. Int J Cancer. 2014 Sep 20. [Epub ahead of print] PubMed PMID: 25242168
  • Micel LN, Tentler JJ, Tan AC, Selby HM, Brunkow KL, Robertson KM, Davis SL, Klauck PJ, Pitts TM, Gangolli E, Fabrey R, O'Connell SM, Vincent PW, Eckhardt SG. Antitumor Activity of the MEK Inhibitor TAK-733 Against Melanoma Cell Lines and Patient-Derived Tumor Explants. Mol Cancer Ther. 2014 Nov 5. [Epub ahead of print] PubMed PMID: 25376610
  • Pitts TM, Newton TP, Bradshaw-Pierce EL, Addison R, Arcaroli JJ, Klauck PJ, Bagby SM, Hyatt SL, Purkey A, Tentler JJ, Tan AC, Messersmith WA, Eckhardt SG, Leong S. Dual Pharmacological Targeting of the MAP Kinase and PI3K/mTOR Pathway in Preclinical Models of Colorectal Cancer. PLoS One. 2014;9(11):e113037. PubMed PMID: 25401499
  • Arcaroli JJ, Quackenbush KS, Purkey A, Powell RW, Pitts TM, Bagby S, Tan AC, Cross B, McPhillips K, Song EK, Tai WM, Winn RA, Bikkavilli K, Vanscoyk M, Eckhardt SG, Messersmith WA. Tumours with elevated levels of the Notch and Wnt pathways exhibit efficacy to PF-03084014, a ?-secretase inhibitor, in a preclinical colorectal explant model. Br J Cancer. 2013 Aug 6;109(3):667-75. PubMed PMID: 23868008
  • Tentler JJ, Ionkina AA, Tan AC, Newton TP, Pitts TM, Glogowska MJ, Kabos P, Sartorius CA, Sullivan KD, Espinosa JM, Eckhardt SG, Diamond JR. p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer. Mol Cancer Ther. 2015 May;14(5):1117-29. PubMed PMID: 25758253
  • Davis SL, Robertson KM, Pitts TM, Tentler JJ, Bradshaw-Pierce EL, Klauck PJ, Bagby SM, Hyatt SL, Selby HM, Spreafico A, Ecsedy JA, Arcaroli JJ, Messersmith WA, Tan AC, Eckhardt SG. Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models. Front Pharmacol. 2015;6:120. PubMed PMID: 26136684
  • Arcaroli JJ, Tai WM, McWilliams R, Bagby S, Blatchford PJ, Varella-Garcia M, Purkey A, Quackenbush KS, Song EK, Pitts TM, Gao D, Lieu C, McManus M, Tan AC, Zheng X, Zhang Q, Ozeck M, Olson P, Jiang ZQ, Kopetz S, Jimeno A, Keysar S, Eckhardt G, Messersmith WA. A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer. Int J Cancer. 2016 Jan 1;138(1):195-205. PubMed PMID: 26152787
  • Lieu CH, Klauck PJ, Henthorn PK, Tentler JJ, Tan AC, Spreafico A, Selby HM, Britt BC, Bagby SM, Arcaroli JJ, Messersmith WA, Pitts TM, Eckhardt SG. Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts. Oncotarget. 2015 Oct 27;6(33):34561-72. PubMed PMID: 26439693
  • Spreafico A, Tentler JJ, Pitts TM, Tan AC, Gregory MA, Arcaroli JJ, Klauck PJ, McManus MC, Hansen RJ, Kim J, Micel LN, Selby HM, Newton TP, McPhillips KL, Gustafson DL, Degregori JV, Messersmith WA, Winn RA, Eckhardt SG. Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer. Clin Cancer Res. 2013 Aug 1;19(15):4149-62. PubMed PMID: 23757356
  • Ryall KA, Kim J, Klauck PJ, Shin J, Yoo M, Ionkina A, Pitts TM, Tentler JJ, Diamond JR, Eckhardt S, Heasley LE, Kang J, Tan AC. An integrated bioinformatics analysis to dissect kinase dependency in triple negative breast cancer. BMC Genomics. 2015 Dec 9;16 Suppl 12:S2. PubMed PMID: 26681397
  • Pitts TM, Kulikowski GN, Tan AC, Murray BW, Arcaroli JJ, Tentler JJ, Spreafico A, Selby HM, Kachaeva MI, McPhillips KL, Britt BC, Bradshaw-Pierce EL, Messersmith WA, Varella-Garcia M, Eckhardt SG. Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models. Front Pharmacol. 2013;4:35. PubMed PMID: 23543898
  • Kessler ER, Eckhardt SG, Pitts TM, Bradshaw-Pierce EL, O'byrant CL, Messersmith WA, Nallapreddy S, Weekes C, Spratlin J, Lieu CH, Kane MA, Eppers S, Freas E, Leong S. Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers. Invest New Drugs. 2015 Dec 30. [Epub ahead of print] PubMed PMID: 26715573
  • Bradshaw-Pierce EL, Pitts TM, Tan AC, McPhillips K, West M, Gustafson DL, Halsey C, Nguyen L, Lee NV, Kan JL, Murray BW, Eckhardt SG. Tumor P-Glycoprotein Correlates with Efficacy of PF-3758309 in in vitro and in vivo Models of Colorectal Cancer. Front Pharmacol. 2013;4:22. PubMed PMID: 23524533
  • Bradshaw-Pierce EL, Pitts TM, Kulikowski G, Selby H, Merz AL, Gustafson DL, Serkova NJ, Eckhardt SG, Weekes CD. Utilization of quantitative in vivo pharmacology approaches to assess combination effects of everolimus and irinotecan in mouse xenograft models of colorectal cancer. PLoS One. 2013;8(3):e58089. PubMed PMID: 23520486
  • Wong KM, Micel LN, Selby HM, Tan AC, Pitts TM, Bagby SM, Spreafico A, Klauck PJ, Blakemore SJ, Smith PF, McDonald A, Berger A, Tentler JJ, Eckhardt SG. Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924). Invest New Drugs. 2016 Oct 25. [Epub ahead of print] PubMed PMID: 27783255
  • Bagby S, Messersmith WA, Pitts TM, Capasso A, Varella-Garcia M, Klauck PJ, Kim J, Tan AC, Eckhardt SG, Tentler JJ, Arcaroli J. Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies. J Vis Exp. 2016 Sep 30;(115). PubMed PMID: 27768028
  • Pitts TM, Bradshaw-Pierce EL, Bagby SM, Hyatt SL, Selby HM, Spreafico A, Tentler JJ, McPhillips K, Klauck PJ, Capasso A, Diamond JR, Davis SL, Tan AC, Arcaroli JJ, Purkey A, Messersmith WA, Ecsedy JA, Eckhardt SG. Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer. Oncotarget. 2016 Aug 2;7(31):50290-50301. PubMed PMID: 27385211
  • Quackenbush KS, Bagby S, Tai WM, Messersmith WA, Schreiber A, Greene J, Kim J, Wang G, Purkey A, Pitts TM, Nguyen A, Gao D, Blatchford P, Capasso A, Schuller AG, Eckhardt SG, Arcaroli JJ. The novel tankyrase inhibitor (AZ1366) enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance. Oncotarget. 2016 May 10;7(19):28273-85. PubMed PMID: 27070088
  • Diamond JR, Eckhardt SG, Tan AC, Newton TP, Selby HM, Brunkow KL, Kachaeva MI, Varella-Garcia M, Pitts TM, Bray MR, Fletcher GC, Tentler JJ. Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models. Clin Cancer Res. 2013 Jan 1;19(1):291-303. PubMed PMID: 23136197
  • Kessler ER, Eckhardt SG, Pitts TM, Bradshaw-Pierce EL, O'byrant CL, Messersmith WA, Nallapreddy S, Weekes C, Spratlin J, Lieu CH, Kane MA, Eppers S, Freas E, Leong S. Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers. Invest New Drugs. 2016 Apr;34(2):176-83. PubMed PMID: 26715573
  • Arcaroli JJ, Tai WM, McWilliams R, Bagby S, Blatchford PJ, Varella-Garcia M, Purkey A, Quackenbush KS, Song EK, Pitts TM, Gao D, Lieu C, McManus M, Tan AC, Zheng X, Zhang Q, Ozeck M, Olson P, Jiang ZQ, Kopetz S, Jimeno A, Keysar S, Eckhardt G, Messersmith WA. A NOTCH1 gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer. Int J Cancer. 2016 Jan 1;138(1):195-205. PubMed PMID: 26152787
  • Klauck PJ, Bagby SM, Capasso A, Bradshaw-Pierce EL, Selby HM, Spreafico A, Tentler JJ, Tan AC, Kim J, Arcaroli JJ, Purkey A, Messersmith WA, Kuida K, Gail Eckhardt S, Pitts TM. Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer. BMC Cancer. 2018 Feb 5;18(1):136. PubMed PMID: 29402316
  • Kiseljak-Vassiliades K, Zhang Y, Bagby S, Kar A, Pozdeyev N, Xu M, Gowan K, Sharma V, Raeburn CD, Albuja-Cruz M, Jones KL, Fishbein L, Schweppe R, Somerset HL, Pitts TM, Leong S, Wierman M. Development of new preclinical models to advance adrenocortical carcinoma research. Endocr Relat Cancer. 2018 Jan 25. [Epub ahead of print] PubMed PMID: 29371329
  • Greene J, Nguyen A, Bagby SM, Jones GN, Tai WM, Quackenbush KS, Schreiber A, Messersmith WA, Devaraj KM, Blatchford P, Eckhardt SG, Cadogan EB, Hughes GD, Smith A, Pitts TM, Arcaroli JJ. The novel ATM inhibitor (AZ31) enhances antitumor activity in patient derived xenografts that are resistant to irinotecan monotherapy. Oncotarget. 2017 Dec 19;8(67):110904-110913. PubMed PMID: 29340025
  • Scott AJ, Song EK, Bagby S, Purkey A, McCarter M, Gajdos C, Quackenbush KS, Cross B, Pitts TM, Tan AC, Eckhardt SG, Fenton H, Arcaroli J, Messersmith WA. Evaluation of the efficacy of dasatinib, a Src/Abl inhibitor, in colorectal cancer cell lines and explant mouse model. PLoS One. 2017;12(11):e0187173. PubMed PMID: 29091939
  • Couts KL, Bemis J, Turner JA, Bagby SM, Murphy D, Christiansen J, Hintzsche JD, Le A, Pitts TM, Wells K, Applegate A, Amato C, Multani P, Chow-Maneval E, Tentler JJ, Shellman YG, Rioth MJ, Tan AC, Gonzalez R, Medina T, Doebele RC, Robinson WA. ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms. Mol Cancer Ther. 2018 Jan;17(1):222-231. PubMed PMID: 29054983
  • Ionkina AA, Tentler JJ, Kim J, Capasso A, Pitts TM, Ryall KA, Howison RR, Kabos P, Sartorius CA, Tan AC, Eckhardt SG, Diamond JR. Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast Cancer. Front Oncol. 2017;7:94. PubMed PMID: 28555173
  • Manuel CA, Bagby SM, Reisinger JA, Pugazhenthi U, Pitts TM, Keysar SB, Arcaroli JJ, Leszczynski JK. Procedure for Horizontal Transfer of Patient-Derived Xenograft Tumors to Eliminate Corynebacterium bovis . J Am Assoc Lab Anim Sci. 2017 Mar 1;56(2):166-172. PubMed PMID: 28315646
  • Wong KM, Micel LN, Selby HM, Tan AC, Pitts TM, Bagby SM, Spreafico A, Klauck PJ, Blakemore SJ, Smith PF, McDonald A, Berger A, Tentler JJ, Eckhardt SG. Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924). Invest New Drugs. 2017 Feb;35(1):11-25. PubMed PMID: 27783255
  • Lang J, Capasso A, Jordan KR, French JD, Kar A, Bagby SM, Barbee J, Yacob BW, Head LS, Tompkins KD, Freed BM, Somerset H, Clark TJ, Pitts TM, Messersmith WA, Eckhardt SG, Wierman ME, Leong S, Kiseljak-Vassiliades K. Development of an Adrenocortical Cancer Humanized Mouse Model to Characterize Anti-PD1 Effects on Tumor Microenvironment. J Clin Endocrinol Metab. 2020 Jan 1;105(1). PubMed PMID: 31513709
  • Schreiber AR, Nguyen A, Bagby SM, Arcaroli JJ, Yacob BW, Quackenbush K, Guy JL, Crowell T, Stringer B, Danaee H, Kalebic T, Messersmith WA, Pitts TM. Evaluation of TAK-264, an Antibody-Drug Conjugate in Pancreatic Cancer Cell Lines and Patient-Derived Xenograft Models. Clin Cancer Drugs. 2018;5(1):42-49. PubMed PMID: 30631747
  • Capasso A, Bagby SM, Dailey KL, Currimjee N, Yacob BW, Ionkina A, Frank JG, Kim DJ, George C, Lee YB, Benaim E, Gittleman B, Hartman SJ, Tan AC, Kim J, Pitts TM, Eckhardt SG, Tentler JJ, Diamond JR. First-in-Class Phosphorylated-p68 Inhibitor RX-5902 Inhibits ß-Catenin Signaling and Demonstrates Antitumor Activity in Triple-Negative Breast Cancer. Mol Cancer Ther. 2019 Nov;18(11):1916-1925. PubMed PMID: 31488700
  • Kar A, Zhang Y, Yacob B, Saeed JM, Tompkins KD, Bagby S, Pitts TM, Somerset HL, Leong S, Wierman M, Kiseljak-Vassiliades K. Targeting PDZ binding kinase is anti-tumorigenic in novel preclinical models of ACC. Endocr Relat Cancer. 2019 Jul 1. [Epub ahead of print] PubMed PMID: 31325906
  • Lennon S, Oweida A, Milner D, Phan AV, Bhatia S, Van Court B, Darragh L, Mueller AC, Raben D, Martínez-Torrecuadrada JL, Pitts TM, Somerset H, Jordan KR, Hansen KC, Williams J, Messersmith WA, Schulick RD, Owens P, Goodman KA, Karam SD. Pancreatic Tumor Microenvironment Modulation by EphB4-ephrinB2 Inhibition and Radiation Combination. Clin Cancer Res. 2019 Jun 1;25(11):3352-3365. PubMed PMID: 30944125
  • Davis SL, Eckhardt SG, Diamond JR, Messersmith WA, Dasari A, Weekes CD, Lieu CH, Kane M, Choon Tan A, Pitts TM, Leong S. A Phase I Dose-Escalation Study of Linsitinib (OSI-906), a Small-Molecule Dual Insulin-Like Growth Factor-1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer. Oncologist. 2018 Dec;23(12):1409-e140. PubMed PMID: 30139840
  • Diamond JR, Eckhardt SG, Pitts TM, van Bokhoven A, Aisner D, Gustafson DL, Capasso A, Sams S, Kabos P, Zolman K, Colvin T, Elias AD, Storniolo AM, Schneider BP, Gao D, Tentler JJ, Borges VF, Miller KD. A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer. Breast Cancer Res. 2018 Aug 2;20(1):82. PubMed PMID: 30071865
  • Capasso A, Lang J, Pitts TM, Jordan KR, Lieu CH, Davis SL, Diamond JR, Kopetz S, Barbee J, Peterson J, Freed BM, Yacob BW, Bagby SM, Messersmith WA, Slansky JE, Pelanda R, Eckhardt SG. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts. J Immunother Cancer. 2019 Feb 8;7(1):37. PubMed PMID: 30736857
  • Capasso A, Pitts TM, Klauck PJ, Bagby SM, Westbrook L, Kaplan J, Soleimani M, Spreafico A, Tentler JJ, Diamond JR, Arcaroli JJ, Messersmith WA, Eckhardt SG, Leong S. Dual compartmental targeting of cell cycle and angiogenic kinases in colorectal cancer models. Anticancer Drugs. 2018 Oct;29(9):827-838. PubMed PMID: 30048249
  • Krishnamurthy A, Dasari A, Noonan AM, Mehnert JM, Lockhart AC, Leong S, Capasso A, Stein MN, Sanoff HK, Lee JJ, Hansen A, Malhotra U, Rippke S, Gustafson DL, Pitts TM, Ellison K, Davis SL, Messersmith WA, Eckhardt SG, Lieu CH. Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer. Cancer Res. 2018 Sep 15;78(18):5398-5407. PubMed PMID: 30042150
  • Scott AJ, Arcaroli JJ, Bagby SM, Yahn R, Huber KM, Serkova NJ, Nguyen A, Kim J, Thorburn A, Vogel J, Quackenbush KS, Capasso A, Schreiber A, Blatchford P, Klauck PJ, Pitts TM, Eckhardt SG, Messersmith WA. Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms. Mol Cancer Ther. 2018 Oct;17(10):2112-2122. PubMed PMID: 30026382
  • Paukovich N, Xue M, Elder JR, Redzic JS, Blue A, Pike H, Miller BG, Pitts TM, Pollock DD, Hansen K, D'Alessandro A, Eisenmesser EZ. Biliverdin Reductase B Dynamics Are Coupled to Coenzyme Binding. J Mol Biol. 2018 Sep 14;430(18 Pt B):3234-3250. PubMed PMID: 29932944
  • Klauck PJ, Bagby SM, Capasso A, Bradshaw-Pierce EL, Selby HM, Spreafico A, Tentler JJ, Tan AC, Kim J, Arcaroli JJ, Purkey A, Messersmith WA, Kuida K, Eckhardt SG, Pitts TM. Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer. BMC Cancer. 2018 Feb 5;18(1):136. PubMed PMID: 29402316
  • Kiseljak-Vassiliades K, Zhang Y, Bagby SM, Kar A, Pozdeyev N, Xu M, Gowan K, Sharma V, Raeburn CD, Albuja-Cruz M, Jones KL, Fishbein L, Schweppe RE, Somerset H, Pitts TM, Leong S, Wierman ME. Development of new preclinical models to advance adrenocortical carcinoma research. Endocr Relat Cancer. 2018 Apr;25(4):437-451. PubMed PMID: 29371329
  • Tentler JJ, Lang J, Capasso A, Kim DJ, Benaim E, Lee YB, Eisen A, Bagby SM, Hartman SJ, Yacob BW, Gittleman B, Pitts TM, Pelanda R, Eckhardt SG, Diamond JR. RX-5902, a novel ß-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer. BMC Cancer. 2020 Nov 4;20(1):1063. PubMed PMID: 33148223
  • Dhar D, Raina K, Kumar D, Wempe MF, Bagby SM, Pitts TM, Orlicky DJ, Agarwal C, Messersmith WA, Agarwal R. Bitter melon juice intake with gemcitabine intervention circumvents resistance to gemcitabine in pancreatic patient-derived xenograft tumors. Mol Carcinog. 2020 Oct;59(10):1227-1240. PubMed PMID: 32816368
  • Abbott JM, Zhou Q, Esquer H, Pike L, Broneske TP, Rinaldetti S, Abraham AD, Ramirez DA, Lunghofer PJ, Pitts TM, Regan DP, Tan AC, Gustafson DL, Messersmith WA, LaBarbera DV. First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer. Mol Cancer Ther. 2020 Aug;19(8):1598-1612. PubMed PMID: 32499299
  • Davis SL, Ionkina AA, Bagby SM, Orth JD, Gittleman B, Marcus JM, Lam ET, Corr BR, O'Bryant CL, Glode AE, Tan AC, Kim J, Tentler JJ, Capasso A, Lopez KL, Gustafson DL, Messersmith WA, Leong S, Eckhardt SG, Pitts TM, Diamond JR. Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors. Clin Cancer Res. 2020 Sep 1;26(17):4633-4642. PubMed PMID: 32414750
  • Duff MR, Redzic JS, Ryan LP, Paukovich N, Zhao R, Nix JC, Pitts TM, Agarwal P, Eisenmesser EZ. Structure, dynamics and function of the evolutionarily changing biliverdin reductase B family. J Biochem. 2020 Aug 1;168(2):191-202. PubMed PMID: 32246827
  • Pitts TM, Simmons DM, Bagby SM, Hartman SJ, Yacob BW, Gittleman B, Tentler JJ, Cittelly D, Ormond DR, Messersmith WA, Eckhardt SG, Diamond JR. Wee1 Inhibition Enhances the Anti-Tumor Effects of Capecitabine in Preclinical Models of Triple-Negative Breast Cancer. Cancers (Basel). 2020 Mar 19;12(3). PubMed PMID: 32204315
  • Lang J, Capasso A, Jordan KR, French JD, Kar A, Bagby SM, Barbee J, Yacob BW, Head LS, Tompkins KD, Freed BM, Somerset H, Clark TJ, Pitts TM, Messersmith WA, Eckhardt SG, Wierman ME, Leong S, Kiseljak-Vassiliades K. Development of an Adrenocortical Cancer Humanized Mouse Model to Characterize Anti-PD1 Effects on Tumor Microenvironment. J Clin Endocrinol Metab. 2020 Jan 1;105(1). PubMed PMID: 31513709
  • Redzic JS, Duff MR, Blue A, Pitts TM, Agarwal P, Eisenmesser EZ. Modulating Enzyme Function via Dynamic Allostery within Biliverdin Reductase B. Front Mol Biosci. 2021;8:691208. PubMed PMID: 34095235
  • Marín-Jiménez JA, Capasso A, Lewis MS, Bagby SM, Hartman SJ, Shulman J, Navarro NM, Yu H, Rivard CJ, Wang X, Barkow JC, Geng D, Kar A, Yingst A, Tufa DM, Dolan JT, Blatchford PJ, Freed BM, Torres RM, Davila E, Slansky JE, Pelanda R, Eckhardt SG, Messersmith WA, Diamond JR, Lieu CH, Verneris MR, Wang JH, Kiseljak-Vassiliades K, Pitts TM, Lang J. Testing Cancer Immunotherapy in a Human Immune System Mouse Model: Correlating Treatment Responses to Human Chimerism, Therapeutic Variables and Immune Cell Phenotypes. Front Immunol. 2021;12:607282. PubMed PMID: 33854497
  • Hartman SJ, Bagby SM, Yacob BW, Simmons DM, MacBeth M, Lieu CH, Davis SL, Leal AD, Tentler JJ, Diamond JR, Eckhardt SG, Messersmith WA, Pitts TM. WEE1 Inhibition in Combination With Targeted Agents and Standard Chemotherapy in Preclinical Models of Pancreatic Ductal Adenocarcinoma. Front Oncol. 2021;11:642328. PubMed PMID: 33869031
  • Lanis JM, Lewis MS, Strassburger H, Bagby SM, Dominguez ATA, Marín-Jiménez JA, Pelanda R, Pitts TM, Lang J. Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors. J Vis Exp. 2022 Dec 16;(190). PubMed PMID: 36591990
  • Lang J, Leal AD, Marín-Jiménez JA, Hartman SJ, Shulman J, Navarro NM, Lewis MS, Capasso A, Bagby SM, Yacob BW, MacBeth M, Freed BM, Eckhardt SG, Jordan K, Blatchford PJ, Pelanda R, Lieu CH, Messersmith WA, Pitts TM. Cabozantinib sensitizes microsatellite stable colorectal cancer to immune checkpoint blockade by immune modulation in human immune system mouse models. Front Oncol. 2022;12:877635. PubMed PMID: 36419897
  • Davis SL, Hartman SJ, Bagby SM, Schlaepfer M, Yacob BW, Tse T, Simmons DM, Diamond JR, Lieu CH, Leal AD, Cadogan EB, Hughes GD, Durant ST, Messersmith WA, Pitts TM. ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer. BMC Cancer. 2022 Oct 29;22(1):1107. PubMed PMID: 36309653
  • Diamond JR, Pitts TM, Ungermannova D, Nasveschuk CG, Zhang G, Phillips AJ, Bagby SM, Pafford J, Yacob BW, Newton TP, Tentler JJ, Gittleman B, Hartman SJ, DeMattei JA, Winkler JD, Wendt MK, Schiemann WP, Eckhardt SG, Liu X, Piscopio AD. Preclinical Development of the Class-I-Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors. Mol Cancer Ther. 2022 Mar 1;21(3):397-406. PubMed PMID: 34965958
  • Amo-Aparicio J, Dominguez A, Atif SM, Dinarello A, Azam T, Alula KM, Piper M, Lieu CH, Lentz RW, Leal AD, Bagby SM, Messersmith WA, Karam SD, Dinarello CA, Pitts TM, Marchetti C. Pancreatic Ductal Adenocarcinoma Cells Regulate NLRP3 Activation to Generate a Tolerogenic Microenvironment. Cancer Res Commun. 2023 Sep 20;3(9):1899-1911. PubMed PMID: 37772994

Specialty Information

Specialties
  • Medical Oncology

School of Medicine

CU Anschutz
Fitzsimons Building

13001 East 17th Place

Aurora, CO 80045

303.724.5375

School
General
Students